tbuckley/cabot-search huggingface dataset:
Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.
Authors: Amr R Ibrahim, Dragana Milojkovic, Marco Bua, Jamshid S Khorshad, Richard Szydlo, Lina Eliasson, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, John M. Goldman, Jane Apperley, David Marin
Journal: Blood (2010)
Randomised trial of indwelling pleural catheters for refractory transudative pleural effusions
Authors: Steven P. Walker, Oliver Bintcliffe, Emma Keenan, Louise Stadon, Matthew Evison, Mohammed Haris, Thapas Nagarajan, Alex West, Alina Ionescu, Benjamin Prudon, Anur Guhan, Rehan Mustafa, Jurgen Herre, David Arnold, Rahul Bhatnagar, Brennan Kahan, Robert F. Miller, Najib M. Rahman, Nick A. Maskell
Journal: European Respiratory Journal (2021)

Refractory symptomatic transudative pleural effusions are an indication for pleural drainage. There has been supportive observational evidence for the use of indwelling pleural catheters (IPCs) for transudative effusions, but no randomised trials. We aimed to investigate the effect of IPCs on breathlessness in patients with transudative pleural effusions when compared with standard care.A multicentre randomised controlled trial, in which patients with transudative pleural effusions were randomly assigned to either an IPC (intervention) or therapeutic thoracentesis (TT; standard care). The primary outcome was mean daily breathlessness score over 12 weeks from randomisation.220 patients were screened from April 2015 to August 2019 across 13 centres, with 33 randomised to intervention (IPC) and 35 to standard care (TT). Underlying aetiology was heart failure in 46 patients, liver failure in 16 and renal failure in six. In primary outcome analysis, the mean±sd breathlessness score over the 12-week study period was 39.7±29.4 mm in the IPC group and 45.0±26.1 mm in the TT group (p=0.67). Secondary outcomes analysis demonstrated that mean±sd drainage was 17 412±17 936 mL and 2901±2416 mL in the IPC and TT groups, respectively. A greater proportion of patients had at least one adverse event in the IPC group (p=0.04).We found no significant difference in breathlessness over 12 weeks between IPCs or TT. TT is associated with fewer complications and IPCs reduced the number of invasive pleural procedures required. Patient preference and circumstances should be considered in selecting the intervention in this cohort.
Myocarditis after Covid-19 mRNA Vaccination
Authors: Amanda K Verma, Kory J Lavine, Chieh-Yu Lin
Journal: New England Journal of Medicine (2021)

Myocarditis after Covid-19 Vaccination Two patients who had received Covid-19 mRNA vaccination are described. One received the BNT162b2 vaccine; the other received the mRNA-1273 vaccine. Myocarditi...
26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results
Authors: Andrew Blauvelt, Baojin Zhu, Mwangi Murage, Jiaying Guo, Terri Ridenour, Mingyang Shan, Russel Burge
Journal: Journal of the American Academy of Dermatology (2021)
26602 A systematic review and meta-analysis of prognostic outcomes of cutaneous squamous cell carcinoma with perineural invasion by anatomical location
Authors: Shirleen Cheng, Kristen Clark, William Guo, Hunya Usmani, Jocellie Marquez, Marissa Ayasse, Evan Jones, Jordan Slutsky
Journal: Journal of the American Academy of Dermatology (2021)
27144 Patient expectations and willingness with teledermatology
Authors: Carey Kim, Abigail Cline, Yasaman Mansouri, Carlos Sarriera, Marian Russo
Journal: Journal of the American Academy of Dermatology (2021)

Background: The COVID-19 pandemic dramatically elevated the importance of telemedicine to the forefront of clinical care. To optimize health care delivery, our study investigated patients' expectation and willingness regarding teledermatology. Methods: We analyzed 247 responses to a 31-question survey evaluating patient expectations and willingness regarding teledermatology. We analyzed responses by gender, race, age, and previous use of telemedicine/teledermatology to evaluate for statistical differences. Results: Seventy-six percent of respondents reported a previous telemedicine visit, while 40% reported a previous teledermatology visit. Respondents were most willing to talk on the phone to discuss an existing dermatological problem and to email with a dermatologist. Respondents were least willing to send digital photos of their own or their childs' skin concern, or to start a new dermatologic medication for their child. Patients without prior teledermatology experience estimated shorter durations of telephone/video calls and were less willing to send digital images. Willingness statistically differed by gender and age (P ˂ .05), but not ethnicity. Males estimated longer durations of video/telephone calls, and were more willing to send photos compared with females (P ˂ .05). Older patients were more willing to start a new medication through teledermatology compared with younger cohorts (P ˂ .05). Caucasians preferred in-office encounters and were less willing to conduct video conferences compared with skin of color patients (P ˂ .05). Conclusion: Insight into patient expectations and willingness for teledermatology is important as electronic telecommunication between patients and physicians expands. Understanding the differences amongst the varied patient demographics can improve health care delivery and clinical outcomes.
The role of Wnt signaling in skin fibrosis
Authors: Michelle F. Griffin, Julika Huber, Fahy J. Evan, Natalina Quarto, Michael T. Longaker
Journal: Medicinal Research Reviews (2021)

Abstract Skin fibrosis is the excessive deposition of extracellular matrix in the dermis. Cutaneous fibrosis can occur following tissue injury, including burns, trauma, and surgery, resulting in scars that are disfiguring, limit movement and cause significant psychological distress for patients. Many molecular pathways have been implicated in the development of skin fibrosis, yet effective treatments to prevent or reverse scarring are unknown. The Wnt signaling pathways are known to play an important role in skin homeostasis, skin injury, and in the development of fibrotic skin diseases. This review provides a detailed overview of the role of the canonical Wnt signaling pathways in regulating skin scarring. We also discuss how Wnt signaling interacts with other known fibrotic molecular pathways to cause skin fibrosis. We further provide a summary of the different Wnt inhibitor types available for treating skin scarring. Understanding the role of the Wnt pathway in cutaneous fibrosis will accelerate the development of effective Wnt modulators for the treatment of skin fibrosis.
Dual Allergy to Penicillin and Cefazolin—Does Anaphylaxis Matter?—Reply
Authors: Meghan N. Jeffres, Bernardo Sousa-Pinto, Kimberly G. Blumenthal
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Erratum to: Dietary Diversification and Specialization in Neotropical Bats Facilitated by Early Molecular Evolution
Authors: Joshua H T Potter, Kalina T J Davies, Laurel R Yohe, Miluska K R Sanchez, Edgardo M Rengifo, Monika Struebig, Kim Warren, Georgia Tsagkogeorga, Burton K Lim, Mario dos Reis, Liliana M Dávalos, Stephen J Rossiter
Journal: Molecular Biology and Evolution (2021)
Fecal miR-142a-3p from dextran sulfate sodium-challenge recovered mice prevents colitis by promoting the growth of Lactobacillus reuteri
Authors: Liuqin He, Xihong Zhou, Yonghui Liu, Lamei Zhou, Fengna Li
Journal: Molecular Therapy (2021)

Feces are enriched with microRNAs (miRNAs) that shape the gut microbiota. These miRNAs are differentially expressed in the feces of healthy and diseased subjects. However, whether fecal miRNAs in subjects with inflammatory bowel diseases are involved in regulating microbiota composition and whether they have any beneficial effects remains unknown. Here, we studied the fecal microbiome composition and miRNA abundance in mice with dextran sulfate sodium (DSS)-induced colitis and mice at the recovery phase to explore different miRNAs expressed, their relations with microbial abundance, and their effects on colitis. We found that miR-142a-3p expression was significantly increased in the feces of mice recovered from colitis and that it could alleviate disease symptoms in mice treated with DSS in a microbiome-dependent manner. Specifically, miR-142a-3p promoted the growth of Lactobacillus reuteri, which had a high abundance in the feces of mice recovered from colitis, by regulating transcripts of polA and locus tag LREU_RS03575. Moreover, L. reuteri, as well as its metabolite reuterin, could alleviate DSS-induced disease symptoms. These results highlight the role of fecal miR-142a-3p in the prevention of colitis. We propose that the feces of subjects who have recovered from diseases might be enriched with miRNAs with preventive effects against those diseases.
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population
Authors: Mette Juul Nielsen, Diana Julie Leeming, Zachary Goodman, Scott Friedman, Peder Frederiksen, Daniel Guldager Kring Rasmussen, Pamela Vig, Star Seyedkazemi, Laurent Fischer, Richard Torstenson, Morten Asser Karsdal, Eric Lefebvre, Arun J. Sanyal, Vlad Ratziu
Journal: Journal of Hepatology (2021)

The development of accurate non-invasive tests to detect and measure the extent of fibrosis and disease activity in patients with non-alcoholic steatohepatitis (NASH) - the progressive phenotype of non-alcoholic fatty liver disease (NAFLD) - is of great clinical importance. Herein, we aimed to validate the performance of PRO-C3 and ADAPT for the detection of moderate/severe fibrosis within the CENTAUR screening population.PRO-C3 was assessed in plasma from the screening population of the phase IIb CENTAUR study (NCT02217475) in adults with NASH and liver fibrosis. The relation between PRO-C3 and histologic features of NASH was evaluated, as well as the demographics of patients with high and low levels of PRO-C3. The diagnostic ability of PRO-C3, as a standalone marker or incorporated into ADAPT, to identify patients with F≥2 and NASH was estimated using receiver-operating characteristic analysis and logistic regression models.A total of 517 individuals with matched biopsy and PRO-C3 measurements were included. Patients with PRO-C3 levels ≥20.2 ng/ml showed increased levels of insulin, HOMA-IR, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and platelet count compared to patients with low PRO-C3 (p <0.05). PRO-C3 increased stepwise with increasing liver fibrosis, lobular inflammation, hepatocyte ballooning, steatosis, and NAFLD activity score (p <0.05), and could distinguish between NAFL and NASH (p <0.0001). PRO-C3 was independently associated with fibrosis and NASH when adjusted for clinical confounders. ADAPT outperformed Fibrosis-4, AST-to-platelet ratio index, and AST/ALT ratio as a predictor of advanced fibrosis and NASH (p <0.001).PRO-C3 was associated with NAFLD activity score and fibrosis. ADAPT outperformed other non-invasive scores for detecting NASH. These data support the use of PRO-C3 and ADAPT as diagnostic tools to identify patients with NASH eligible for inclusion in clinical trials.NCT02217475 LAY SUMMARY: PRO-C3 is a serological biomarker associated with liver disease activity and fibrosis. Its performance for the detection of disease activity and fibrosis is improved when it is incorporated into the ADAPT score. Herein, we showed that ADAPT was better at selecting patients with non-alcoholic steatohepatitis for inclusion in clinical trials than other non-invasive scores.
International migration of unaccompanied minors: trends, health risks, and legal protection
Authors: Susanna Corona Maioli, Jacqueline Bhabha, Kolitha Wickramage, Laura C N Wood, Ludivine Erragne, Omar Ortega García, Rochelle Burgess, Vasileia Digidiki, Robert W Aldridge, Delan Devakumar
Journal: The Lancet Child & Adolescent Health (2021)
27389 Rapid and sustained improvement in itch in children aged 6–11 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial
Authors: Amy S. Paller, Elaine C. Siegfried, Gil Yosipovitch, Jonathan I. Silverberg, Jashin J. Wu, Zhen Chen, Randy Prescilla, Ana B. Rossi, Dimittri Delevry
Journal: Journal of the American Academy of Dermatology (2021)
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
Authors: Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V. Revuelta, Leandro Cerchietti, John P. Leonard
Journal: Blood (2021)

Abstract Resistance to standard immunochemotherapy remains an unmet challenge in diffuse large B-cell lymphoma (DLBCL), and aberrant DNA methylation may contribute to chemoresistance. Promising early-phase results were reported with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus subcutaneous azacitidine, a hypomethylating agent. In this phase 1 study, we evaluated CC-486 (oral azacitidine) plus 6 cycles of R-CHOP in patients with previously untreated intermediate- to high-risk DLBCL or grade 3B/transformed follicular lymphoma. CC-486 doses of 100, 150, 200, or 300 mg given 7 days before cycle 1 and on days 8-21 of cycles 1-5 were evaluated; additional patients were enrolled in the expansion phase to examine preliminary efficacy. The primary objectives were to determine the safety and the maximum tolerated dose (MTD) of CC-486 in combination with R-CHOP. The most common grade 3/4 toxicities were hematologic, including neutropenia (62.7%) and febrile neutropenia (25.4%); grade 3/4 nonhematologic toxicities were uncommon (&amp;lt;7%). The MTD was not established; 2 patients had dose-limiting toxicities (1 with grade 4 febrile neutropenia; 1 with grade 4 prolonged neutropenia). The recommended phase 2 dose was established as 300 mg. The overall response rate was 94.9%, with 52 patients (88.1%) achieving complete responses. With a median follow-up of 28.9 months, estimated 1- and 2-year progression-free survival rates were 84.1% and 78.6%, respectively. Overall, epigenetic priming with CC-486 before R-CHOP can be delivered with acceptable safety to patients with previously untreated intermediate- to high-risk DLBCL or grade 3B/transformed follicular lymphoma. ClinicalTrials.gov: NCT02343536.
Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.
Authors: Lin Shen, Jifang Gong, Jian Zhang, Dongmei Ji, Haijun Zhong, Ying Yuan, Lei Yang, Qingyuan Zhang, Yufeng Li, Mengde Wang, Chuan Qi, Zhenzhong Xia, Lingmin Lu, John Huang, Ling Sun, Li Xu, Michael Shi, Xichun Hu
Journal: Journal of Clinical Oncology (2021)

e14547 Background: MSB2311 is a novel humanized PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration. Methods: Patients with metastatic solid tumors or selected lymphoma progressed on or after standard treatments were enrolled in this phase I study. In dose escalation part, MSB2311 was given at dose levels of 3, 10, and 20 mg/kg intravenously every 3 weeks. At the dose expansion part, patients with enriched biomarker expression, including EBV+, PD-L1+ (TPS≥50%), MSI-High or TMB-High (≥10muts/Mb), were dosed at 20mg/kg Q3W or 10mg/kg Q2W. Primary objectives are to evaluate the safety and tolerability and to identify MTD and RP2D. Secondary objectives include the assessment of pharmacokinetic parameter, immunogenicity, and preliminary anti-cancer activity per RECIST1.1. Results: As of data cutoff by Aug 31, 2020, 33 Chinese patients had been treated, including 27 heavily pre-treated solid tumor patients and 6 lymphoma patients. No dose limiting toxicity was reported and MTD has not been reached. The most common AEs (&gt;20%) included: anemia, hypothyroidism, aspartate aminotransferase elevated, proteinuria, weight loss. 13 patients (39.4%) experienced grade 3 AEs, and 6 patients (18.2%) experienced SAEs. No treatment related grade 4 or 5 event was reported. Of the 17 efficacy evaluable solid tumor patients with biomarker selection, 6 achieved confirmed partial response with 35% ORR: 2/8 (25%) at 10 mg/kg Q2W and 4/9 (44%) at 20 mg/kg Q3W. Additionally, one patient achieved sustained iPR via iRECIST. 4 out of 7 responding patients (including one iPR) achieved tumor shrinkage of more than 50%, 3 of them got durable response (≥24 weeks).1 out of 6 lymphoma patients achieved PR. Conclusions: MSB2311 demonstrated a manageable safety profile and promising preliminary antitumor activity in patients with advanced solid tumors and selected lymphomas. Clinical trial information: NCT04272944.
Wide QRS Complex Bradycardia in a Hemodynamically Unstable Young Woman
Authors: Sascha Macherey, Jan-Malte Sinning, Victor Mauri
Journal: Circulation (2021)

A 33-years old female patient was transferred to the emergency department after out-of-hospital cardiac arrest.The prehospital ECG showed a regular bradycardia with wide QRS complex (see Figure 1) that subsequently converted into ventricular fibrillation requiring cardiopulmonary resuscitation.The patient was intubated and sedated.The medical history of the patient was negative for chronic disease.The patient's personal belongings included a box with aromatic green plant needles.Acute myocardial infarction, acute aortic syndrome, and pulmonary embolism were excluded by coronary angiography
Validation of the Association of Oral Corticosteroid Bursts With Adverse Events in Children—Reply
Authors: Tsung-Chieh Yao, Ann Chen Wu, Hui-Ju Tsai
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Supporting victims of sexual assault: the forensic medicine doctor
Authors: Helen Jones
Journal: BMJ (2021)

Supporting victims of sexual assault: the forensic medicine doctor Specialty doctor Bernadette Butler cares for patients who have been raped or sexually assaulted.She talks to Helen Jones about her work and the importance of forensic medicine Helen Jones"It can be difficult work but knowing that we offer patients somewhere to get help and advice helps me to cope," says Bernadette Butler.She is clinical education and training lead for the Havens, a group of three specialist centres run by King's College Hospital NHS Foundation Trust for anyone who has been raped or sexually assaulted.
A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1
Authors: Wei Li, Saiyu Hang, Yuan Fang, Sena Bae, Yancong Zhang, Minghao Zhang, Gang Wang, Megan D. McCurry, Munhyung Bae, Donggi Paik, Eric A. Franzosa, Fraydoon Rastinejad, Curtis Huttenhower, Lina Yao, A. Sloan Devlin, Jun R. Huh
Journal: Cell Host & Microbe (2021)
Covid-19: UK approves first monoclonal antibody treatment
Authors: Elisabeth Mahase
Journal: BMJ (2021)

<h3>Abstract</h3> Hominin evolution is characterized by progressive regional differentiation, as well as migration waves, leading to anatomically modern humans that are assumed to have emerged in Africa and spread over the whole world. Why or whether Africa was the source region of modern humans and what caused their spread remains subject of ongoing debate. We present a spatially explicit, stochastic numerical model that includes ongoing mutations, demic diffusion, assortative mating and migration waves. Diffusion and assortative mating alone result in a structured population with relatively homogeneous regions bound by sharp clines. The addition of migration waves results in a power-law distribution of wave areas: for every large wave, many more small waves are expected to occur. This suggests that one or more out-of-Africa migrations would probably have been accompanied by numerous smaller migration waves across the world. The migration waves are considered “spontaneous”, as the current model excludes environmental or other factors. Large waves preferentially emanate from the central areas of large, compact inhabited areas. During the Pleistocene, Africa was the largest such area most of the time, making Africa the statistically most likely origin of anatomically modern humans, without a need to invoke additional environmental or ecological drivers.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Authors: Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. Tallman, Tait D. Shanafelt, Neil E. Kay
Journal: Blood (2021)